Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer ...

SHANGHAI, July 14 (Reuters) - AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its ...

Scientists have developed a new method for accurately predicting gene changes that cause lung cancer, without the need for ...

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal ...

Non-small-cell lung cancer (NSCLC) treatment has changed a lot in recent years. Your doctor may check your lung cancer cells for certain DNA changes. If no DNA changes are found, it is called ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

AstraZeneca Plc will pay China’s Dizal Jiangsu Pharmaceutical Co. $600 million upfront for global rights to a lung cancer ...

Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...

Most lung cancers aren’t diagnosed until you’re older. In fact, on average, lung cancer shows up around the age of 70. The most common type is non-small-cell lung cancer (NSCLC), which grows from the ...